Silo Pharma Board Authorizes $1 Million Share Repurchase Program
Board authorized repurchase of up to $1 million of common stock via open-market or private transactions, signaling management confidence. Company had 13,318,273 shares outstanding as of Nov. 13, 2025, with timing, volume, and pricing dependent on market conditions and regulatory constraints.
1. Program Authorization and Structure
Silo Pharma’s board has approved a share repurchase program authorizing up to $1 million of common stock acquisitions. Purchases may occur on the open market or through privately negotiated transactions, all in compliance with SEC regulations and applicable legal requirements.
2. Outstanding Share Base
As of November 13, 2025, the company reported 13,318,273 shares of common stock outstanding. The actual number of shares repurchased will depend on prevailing share prices and liquidity in the trading market.
3. Management Rationale and Potential Impact
Management believes current capital market conditions allow Silo Pharma to capture additional shareholder value through measured buybacks. The program may reduce the public float, potentially enhancing earnings per share and supporting the stock price, though timing will respect blackout periods and may be suspended at the board’s discretion.